Anticoagulant News and Research RSS Feed - Anticoagulant News and Research

Cardiovascular considerations crucial for CML TKI patients

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
MUSC researchers receive PCORI grant to study safety, effectiveness of three blood-thinning drugs

MUSC researchers receive PCORI grant to study safety, effectiveness of three blood-thinning drugs

A research team at the Medical University of South Carolina has been approved for a $13.5 million funding award by the Patient-Centered Outcomes Research Institute to study the safety and effectiveness of three blood-thinning drugs used to prevent potentially deadly blood clots in patients undergoing hip and knee replacement. [More]
Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding. [More]
American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

The American College of Cardiology has launched a new STS/ACC TAVR In-Hospital Mortality Risk App and an extensively overhauled the ACC AnticoagEvaluator App, bolstering its expansive Clinical App Collection. With these new and improved apps, the ACC continues to diversify the clinical content and decision support it offers clinicians in the mobile space. [More]
Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published online in the Journal of the American College of Surgeons ahead of print publication early next year. [More]
XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research. [More]
Older patients can recover from acute subdural hematomas

Older patients can recover from acute subdural hematomas

According to a study completed at the Helsinki University Hospital Department of Neurosurgery, even patients over the age of 75 may recover from severe traumatic brain injury. This is the first study to describe the results of surgically treated elderly patients with acute subdural hematomas. [More]
Columbia University data scientists create world's first catalog of therapeutic venom

Columbia University data scientists create world's first catalog of therapeutic venom

What doesn't kill you could cure you. A growing interest in the therapeutic value of animal venom has led a pair of Columbia University data scientists to create the first catalog of known animal toxins and their physiological effects on humans. [More]
New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

Medical Compression Systems, Inc. (MCS), today announced new data further validating the use of the ActiveCare DVT prophylaxis compression system following total joint replacement procedures. [More]
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]
Screening for asymptomatic atrial fibrillation could reduce risk of stroke, premature death

Screening for asymptomatic atrial fibrillation could reduce risk of stroke, premature death

Screening for asymptomatic atrial fibrillation (AF) in people aged 65 and over and treating it with anticoagulant medications could greatly reduce the risk of stroke and premature death, say cardiologists in today's Journal of the American Medical Association. [More]
FDA grants accelerated approval to Praxbind (idarucizumab)

FDA grants accelerated approval to Praxbind (idarucizumab)

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects. [More]
Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. [More]
AF patients treated with rivaroxaban for stroke prevention experience low rates of bleeding and stroke

AF patients treated with rivaroxaban for stroke prevention experience low rates of bleeding and stroke

Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study presented at ESC Congress today. [More]
SLU scientist receives grant to solve blood-clotting mysteries

SLU scientist receives grant to solve blood-clotting mysteries

Last summer, SLU scientists made a breakthrough discovery about the way in which blood clots. Through X-ray crystallography, they solved the molecular structure of prothrombin, an important blood-clotting protein, revealing an unexpected, flexible role for a "linker" region that may be the key to developing better life-saving drugs. [More]
GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) showcased at ESC Congress 2015 expose that all-cause death was the most frequent major event in more than 17,000 newly diagnosed AF patients, far exceeding the rate of stroke or major bleeding. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial. [More]
Educational program does not influence patients’ adherence to apixaban anticoagulant

Educational program does not influence patients’ adherence to apixaban anticoagulant

Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show. [More]
Advertisement
Advertisement